Document › Details

Life Technologies Corporation. (12/16/09). "Press Release: Life Technologies’ SOLiD System Finds Mutations in Small Cell Lung Cancer Line. Paper Published in Nature Demonstrates Mutational Burden Caused by Tobacco Smoking". Carlsbad, CA.

Organisations Organisation Applied Biosystems (ABI) (unit of Life Technologies)
  Group Life Technologies (Group)
  Organisation 2 Wellcome Trust Cancer Center
  Group Wellcome Trust, The
Products Product SOLiD™ 2.0 DNA sequencing system
  Product 2 DNA sequencing
Index terms Index term Wellcome Trust–Applera: cancer genomics, 200805–200812 collab sequencing cancer + normal DNA from same individual using SOLiD™ ABI + Sanger Institute
  Index term 2 small cell lung cancer (SCLC)
Person Person Miller, Kip (Life Technologies 200904 President Genetic Systems Division before Invitrogen)
     
Applied Biosystems, part of LifeTechnologies Corporation (NASDAQ:LIFE), today announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking. The paper, authored by researchers from the Wellcome Trust Cancer Institute and co-authored by Applied Biosystems, demonstrates the potential for next-generation sequencing to provide unprecedented insights into mutational processes, cellular repair pathways and gene networks associated with cancer development.

"The publication of this paper emphasizes the power that next-generation sequencing, such as Applied Biosystems' SOLiD(TM) System, has to improve science's understanding of disease and its potential to develop better diagnostics and therapeutic treatment," said Kip Miller, President, Genetic Systems for Life Technologies. "Today's SOLiD 3 Plus System offers even more capability and is faster, more robust and more economical than the SOLiD 2.0 System that generated the data in the paper."

These impactful results were generated at the Sanger Institute using an early version of the SOLiD System. Massively parallel sequencing on Applied Biosystems' SOLiD 2.0 System enabled the researchers to identify all of the mutations in the SCLC line NCI-H209 and compare them to a matched normal cell line. Data identified several mutation signatures that reflect the wide range of carcinogens in tobacco smoke, which is notable because 90 percent of patients with SCLC smoked during their lives.

Today's SOLiD 3 Plus System is capable of generating over 60Gb of mappable sequence at an accuracy greater than 99.95 percent.

To read the complete paper, please visit http://www.nature.com/nature/journal/vaop/ncurrent/full/nature08629.html.

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Corporation
Patty Zamora,
760-476-7818
patty.zamora@lifetech.com


   
Record changed: 2010-07-21

More documents for Life Technologies (Group)

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
» top